pDONR221_SLC35B2 Citations (1)
Originally described in: The RESOLUTE consortium: unlocking SLC transporters for drug discovery.Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gurtl B, Klavins K, Klimek C, Lindinger S, Lineiro-Retes E, Muller AC, Onstein S, Redinger G, Reil D, Sedlyarov V, Wolf G, Crawford M, Everley R, ... Steppan CM Nat Rev Drug Discov. 2020 Jul;19(7):429-430. doi: 10.1038/d41573-020-00056-6. PubMed Journal
Articles Citing pDONR221_SLC35B2
| Articles |
|---|
| Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Dieter SM, Lovecchio D, Pataskar A, Zowada MK, Korner PR, Khalizieva A, van Tellingen O, Jager D, Glimm H, Agami R. Oncogene. 2022 Aug;41(32):3953-3968. doi: 10.1038/s41388-022-02400-z. Epub 2022 Jul 7. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.